Proveca Pharma

Executive Summary

Proveca Pharma is a UK-based specialty pharmaceutical company addressing the critical unmet need for age-appropriate, licensed medicines in children. Focused on neurology and cardiology, the company develops and licenses formulations specifically designed for pediatric populations, where many treatments are currently used off-label or in unsuitable adult formats. Founded in 2011 and privately held, Proveca has built a portfolio of differentiated products that aim to improve safety, dosing accuracy, and compliance in children. By targeting areas with high medical need and limited competition, the company is positioned to capture value in the niche but growing pediatric pharmaceutical market. Recent progress includes advancing its pipeline through regulatory pathways and seeking strategic partnerships to expand commercial reach. With a lean operating model and expertise in pediatric drug development, Proveca is poised to deliver meaningful growth and improve outcomes for young patients.

Upcoming Catalysts (preview)

• Q2 2026Regulatory approval or marketing authorization for lead pediatric product in EU/UK70% success
• H2 2026Partnership or licensing deal for one of its cardiology or neurology assets60% success